Expertise in
40
conditions

Dr. Kevin P. Redmond

Radiation Oncology
West Chester Hospital Radiotherapy Center
7710 Discovery Dr, 
West Chester, OH 
Accepting New Patients
44 Years of Experience
Expertise in
40
conditions
West Chester Hospital Radiotherapy Center
7710 Discovery Dr, 
West Chester, OH 

Overview

Kevin Redmond is a Radiation Oncologist practicing medicine in West Chester, Ohio. He has been practicing medicine for over 44 years.

Dr. Redmond is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Oral Squamous Cell Carcinoma, Lung Cancer, Pleuropulmonary Blastoma, and Familial Prostate Cancer.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 12 clinical trials. Dr. Redmond is currently accepting new patients.

Graduate Year

1982

Specialties

Radiation Oncology

Licenses

Radiology in OH

Hospital Affiliations

West Chester Hospital
University Of Cincinnati Medical Center, LLC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

West Chester Hospital Radiotherapy Center
7710 Discovery Dr, West Chester, OH 45069

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: July 13, 2026
Intervention Type: Radiation
Study Phase: Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Radiation
Study Phase: Phase 1
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

7 Total Publications

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
Journal: The Lancet. Oncology
Published: September 20, 2022
Similar Doctors
Expertise in
17
conditions
Dr. Jordan R. Kharofa
Radiation Oncology
Expertise in
17
conditions
Dr. Jordan R. Kharofa
Radiation Oncology
Referral may be required

West Chester Hospital Radiotherapy Center

7710 Discovery Dr, 
West Chester, OH 
 (0.1 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jordan Kharofa is a Radiation Oncologist practicing medicine in West Chester, Ohio. He has been practicing medicine for over 17 years. Dr. Kharofa is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Anal Cancer, Pancreatic Cancer, Vaginal Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Kharofa is currently accepting new patients.

Expertise in
25
conditions
Dr. Timothy D. Struve
Radiation Oncology
Expertise in
25
conditions
Dr. Timothy D. Struve
Radiation Oncology
Referral may be required

West Chester Hospital Radiotherapy Center

7710 Discovery Dr, 
West Chester, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Struve is a Radiation Oncologist practicing medicine in West Chester, Ohio. Dr. Struve is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Metastatic Brain Tumor, and Prostate Cancer. Dr. Struve is currently accepting new patients.

Expertise in
8
conditions
Dr. Teresa M. Meier
Radiation Oncology
Expertise in
8
conditions
Dr. Teresa M. Meier
Radiation Oncology
Referral may be required

West Chester Hospital Radiotherapy Center

7710 Discovery Dr, 
West Chester, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Teresa Meier is a Radiation Oncologist practicing medicine in West Chester, Ohio. Dr. Meier is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Breast Cancer, and Endometrial Cancer. Dr. Meier is currently accepting new patients.

Frequently Asked Questions about Dr. Kevin P. Redmond

How do I make an appointment with Dr. Kevin P. Redmond?

You can book an appointment with Dr. Kevin P. Redmond by calling their office at 513-475-7777. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin P. Redmond a top-rated expert for Oral Squamous Cell Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin P. Redmond is classified as an Distinguished expert for Oral Squamous Cell Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin P. Redmond specialize in?

While Dr. Kevin P. Redmond is a Radiation Oncology, they have specific expertise in Oral Squamous Cell Carcinoma, Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Kevin P. Redmond participate in research or clinical trials?

Yes. Dr. Kevin P. Redmond has published 7 articles and abstracts on conditions like Oral Squamous Cell Carcinoma. You can view a list of Dr. Kevin P. Redmond's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kevin P. Redmond accept my insurance?

Dr. Kevin P. Redmond accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 513-475-7777 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Redmond's expertise for a condition
ConditionClose
    View All 35 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile